Blincyto IV infusion 35μg contains blinatumomab (genetical recombination) and is manufactured by Amgen. This injectable drug (YJ code: 4291445D1029) is supplied as 35μg per bottle with infusion stabilization solution, used for treating B-cell precursor acute lymphoblastic leukemia.
Blincyto IV infusion 35μg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
